Navigation Links
Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium
Date:9/8/2011

s, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact    
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41-(0)21-321-01-11
Fax: +41-(0)21-321-01-69
mwagner@debiopharm.com

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44-(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Lena Evans
Account Executive
Tel:  +1-212-845-4262
Fax: +1-212-845-4260
lena.evans@russopartnersllc.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... and SOUTH SAN FRANCISCO, Calif. ... the venture arm of Baxter International Inc. (NYSE: ... LLC ("VPD") today announced the formation of Vitesse Biologics, ... by Baxter Ventures to focus on the development of ... hematology, and oncology. Following the spin-off of Baxter BioScience ...
(Date:6/1/2015)... /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") today ... the ERA-EDTA Congress in London, England ... First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects ... (CKD); a Post-hoc Analysis of Patients from the ASSERT, ... Kam Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension ...
(Date:6/1/2015)... , June 1, 2015   Epic Sciences, ... develops products and offerings to personalize and advance the ... has expanded the available credit under its existing credit ... amended agreement increases the available capacity of the facility ... the maturity by 27 months to April 1, 2019. ...
(Date:6/1/2015)... , May 29, 2015 Research ... the addition of the "2015 Strategies ... report to their offering. This ... European immunoprotein diagnostic market, including emerging tests, ... strategic profiles of leading suppliers. ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Sept. 10 Abeome Corporation, a,Georgia-based biotech company, ... (SAB) to collaborate on the development of,Abeome,s ovarian ... therapeutic,and diagnostic projects for the company., The ... Meagher, PhD, Chief,Scientific Officer for Abeome, Distinguished Research ...
... Generation of Drug Candidates ... for Inflammatory Diseases, ... Cellzome Inc. and GlaxoSmithKline (LSE & NYSE:,GSK) announce the ... novel kinase-targeted therapeutics to treat inflammatory,diseases., The alliance gives ...
... Sept. 9 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), ... wave of,antibody therapeutics, today announced that RiskMetrics ISS ... they have no,objection to the transaction, and are ... the proposed plan of arrangement whereby Roche,will acquire ...
Cached Biology Technology:Abeome Forms First Class Scientific Advisory Board 2GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 2GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 3GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 4Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 2Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 3
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... Manipulation of cells by a new microfluidic device may ... the body,s own immune cells to fight such diseases ... neuroblastoma. The therapy, known as adoptive T cell ... treatment involves removing disease-fighting immune cells called T cells ...
... engineered bacteria to churn out a gasoline-like biofuel at ... breakthrough that could soon provide an affordable and "green" ... week in advance of publication in the journal ... assistant professor of chemistry at UC Berkeley, graduate student ...
... NJ The American Heart Association estimates 35 percent of ... of risk factors characterized by obesity and the simultaneous presence ... sugar and lipids. In patients with metabolic syndrome, high ... in turn affects the organ,s ability to filter waste from ...
Cached Biology News:Researchers predict age of T cells to improve cancer treatment 2Researchers predict age of T cells to improve cancer treatment 3Turning bacteria into butanol biofuel factories 2Turning bacteria into butanol biofuel factories 3Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 2Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 3
Buffer used for mitocapture assays....
... CyScribe GFX Purification Kit, 25 ... CyDye labeled cDNA probesProvides efficient removal ... from labeling reactions with superior yields ... for the purification of cDNA labeled ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Biology Products: